首页> 外文会议>World congress of the International Photodynamic Association >Results of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) in treatment of obstructive endobronchial non-small cell lung cancer
【24h】

Results of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) in treatment of obstructive endobronchial non-small cell lung cancer

机译:相比光动力治疗(PDT)和高剂量率近距离放射治疗(HDR)治疗阻塞性骨架非小细胞肺癌的结果

获取原文

摘要

Introduction: We reviewed the outcome of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) for patients with symptomatic obstruction from endobronchial non-small cell lung cancer. Methods: Nine patients who received combined PDT and HDR for endobronchial cancers were identified and their charts reviewed. The patients were eight males and one female aged 52-73 at diagnosis, initially presenting with various stages of disease: stage IA (N=1), stage IIA (N=1), stage III (N=6), and stage IV (N=1). Intervention was with HDR (500 cGy to 5 mm once weekly for 3 weeks) and PDT (2 mg/kg Photofrin?, followed by 200 J/cm~2 illumination 48 hours post infusion). Treatment group 1 (TG-1, N=7) received HDR first; Treatment group 2 (TG-2, N=2) received PDT first. Patients were followed by regular bronchoscopies. Results: Treatments were well tolerated, all patients completed therapy, and none were lost to follow-up. In TG-1, local tumor control was achieved in six of seven patients for: 3 months (until death), 15 months, 2+ years (until death), 2+ years (ongoing), and 5+ years (ongoing, N=2). In TG-2, local control was achieved in only one patient, for 84 days. Morbidities included: stenosis and/or other reversible benign local tissue reactions (N=8); photosensitivity reaction (N=2), and self-limited pleural effusion (N=2). Conclusions: Combined HDR/PDT treatment for endobronchial tumors is well tolerated and can achieve prolonged local control with acceptable morbidity when PDT follows HDR and when the spacing between treatments is one month or less. This treatment regimen should be studied in a larger patient population.
机译:介绍:我们审查了对症状非小细胞肺癌症状梗阻患者的患者组合光动力治疗(PDT)和高剂量速率近距离放射治疗(HDR)的结果。方法:确定了九个接受PDT和HDR用于内核癌症的患者及其图表审查。患者是八个男性和一个女性52-73岁,诊断,最初呈现各个疾病阶段:阶段IA(n = 1),阶段IIA(n = 1),III阶段(n = 6)和第四阶段(n = 1)。干预用HDR(每周500 cgy至5毫米,3周)和PDT(2mg / kg Photofrin?,后续输注后48小时200 J / cm〜2照明)。治疗组1(TG-1,N = 7)首先接受HDR;治疗组2(TG-2,N = 2)首先接受PDT。患者之后是常规支气管镜检查。结果:治疗耐受性良好,所有患者完成治疗,没有人失去随访。在TG-1中,局部肿瘤对照中的六个患者中的六个患者达到:3个月(直至死亡),15个月,2年以上(直到死亡),2年以上(持续),5年以上(持续,N = 2)。在TG-2中,仅在一个患者中达到局部对照84天。条例包括:狭窄和/或其他可逆良性局部组织反应(n = 8);光敏性反应(n = 2),以及自限胸腔积液(n = 2)。结论:结合HDR / PDT治疗的内核肿瘤是良好的耐受性,并且当PDT遵循HDR时,可以在PDT和治疗之间间距为一个月或更短时间时,可以达到局部局部对照。应在更大的患者群体中研究这种治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号